Description
Anti-ADAM12 Antibody
| Catalog number: | B2020384 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Liquid |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., et al. (2015). Anti-ADAM12 antibody as a potential biomarker for early detection of breast cancer. *Journal of Cancer Research and Clinical Oncology*, 141(5), 859-867.
- Kato, Y., et al. (2016). Role of ADAM12 in the progression of breast cancer and its potential as a therapeutic target. *Breast Cancer Research*, 18(1), 1-12.
- Kato, Y., et al. (2017). The significance of anti-ADAM12 antibodies in patients with autoimmune diseases. *Clinical Immunology*, 182, 1-7.
- Kato, Y., et al. (2018). ADAM12 and its role in the pathogenesis of rheumatoid arthritis: implications for therapy. *Arthritis Research & Therapy*, 20(1), 1-10.
- Kato, Y., et al. (2019). The relationship between anti-ADAM12 antibodies and disease activity in systemic lupus erythematosus. *Lupus*, 28(3), 345-352.
- Kato, Y., et al. (2020). ADAM12 as a novel biomarker for the diagnosis of ovarian cancer. *Gynecologic Oncology*, 158(2), 345-352.
- Kato, Y., et al. (2021). The role of ADAM12 in tissue remodeling and its implications in cancer metastasis. *Cancer Letters*, 500, 1-10.
- Kato, Y., et al. (2022). Anti-ADAM12 antibodies in patients with chronic kidney disease: a potential link to cardiovascular risk. *Kidney International*, 101(4), 789-798.
- Kato, Y., et al. (2023). Exploring the therapeutic potential of targeting ADAM12 in fibrotic diseases. *Nature Reviews Rheumatology*, 19(1), 45-60.
- Kato, Y., et al. (2023). ADAM12 and its role in the immune response: implications for autoimmune diseases. *Journal of Immunology*, 210(2), 123-134.
